Literature DB >> 25521108

CO2 laser treatment for regional cutaneous malignant melanoma metastases.

Jorien A van Jarwaarde1, Ronnie Wessels, Omgo E Nieweg, Michel W J M Wouters, Jos A van der Hage.   

Abstract

BACKGROUND: Cutaneous in-transit and satellite metastases are distressing presentations of melanoma progression.
OBJECTIVE: The purpose of this study was to analyze the efficacy of carbon dioxide (CO2) lasers in patients with melanoma with cutaneous in-transit and satellite metastases.
MATERIALS AND METHODS: Results of CO2 laser therapy were retrospectively evaluated in 22 patients between January 2004 and January 2008. The number of laser treatments, postoperative morbidity, regional control, and overall survival were analyzed.
RESULTS: Twenty-two patients received a total of 42 CO2 laser treatments. The number of lesions treated per session varied from 3 to 329. The median duration of regional control in all patients was 14 weeks (range, 3-117). In 9 of 22 patients, only 1 treatment with CO2 laser was performed resulting in a mean regional control of 11 weeks. In 10 patients, an average of 4 laser treatments (range, 1-17) was necessary to achieve regional control. Three of the 22 patients underwent isolated limb perfusion after laser treatment for disease control.
CONCLUSION: This study shows that (repeated) laser treatment can achieve adequate regional control with little morbidity. CO2 laser is recommended as a first-line treatment to patients with small but numerous cutaneous satellite or in-transit lesions in whom other surgery would induce substantial morbidity.

Entities:  

Mesh:

Year:  2015        PMID: 25521108     DOI: 10.1097/DSS.0000000000000251

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  6 in total

1.  Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

Authors:  F C Wright; S Kellett; N J Look Hong; A Y Sun; T P Hanna; C Nessim; C A Giacomantonio; C F Temple-Oberle; X Song; T M Petrella
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

2.  Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy.

Authors:  Jung Hyun Han; Youngmin Moon; Jong Jin Lee; Sujeong Choi; Yong-Chul Kim; Sungho Jeong
Journal:  Biomed Opt Express       Date:  2015-12-08       Impact factor: 3.732

3.  Application of CO2 laser evaporation in locally advanced melanoma.

Authors:  Otis M Vrielink; Schelto Kruijff; Barbara L van Leeuwen; Jan Ln Roodenburg
Journal:  Melanoma Manag       Date:  2019-04-18

Review 4.  Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.

Authors:  Alexander C J van Akkooi; Lisanne P Zijlker; Michel W J M Wouters
Journal:  BioDrugs       Date:  2022-04-09       Impact factor: 7.744

5.  Three Hundred Patients Treated with Ultrapulsed 980 nm Diode Laser for Skin Disorders.

Authors:  Uwe Wollina
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

6.  Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy.

Authors:  Raphael Reinhard; Christoffer Gebhardt; Nolwenn Maurier; Lionel Larribère; Azadeh Orouji; Jochen Utikal
Journal:  JAAD Case Rep       Date:  2018-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.